[New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects].
Ter Arkh
; 93(9): 1132-1137, 2021 Sep 15.
Artículo
en Ruso
| MEDLINE | ID: covidwho-1486854
ABSTRACT
Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to new information about its antifibrotic and antiproliferative effects, both cardiac and extracardiac. The article also discusses the possibility of using spironolactone in patients with the new coronavirus infection SARS-CoV-2 (COVID-19).
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Tratamiento Farmacológico de COVID-19
/
Hipertensión
Tipo de estudio:
Estudio experimental
/
Estudio pronóstico
Límite:
Humanos
Idioma:
Ruso
Revista:
Ter Arkh
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS